Literature DB >> 16752435

Multi-centre first-trimester screening for Down syndrome in the Netherlands in routine clinical practice.

P C J I Schielen1, M van Leeuwen-Spruijt, I Belmouden, L H Elvers, M Jonker, J G Loeber.   

Abstract

OBJECTIVES: This is the first report on the results of a first-trimester combined-test screening programme in the Netherlands in a multi-centre routine clinical setting.
METHODS: Between July 2002 and May 2004, blood samples were taken from subjects in 44 centres in the Netherlands and sent to our laboratory to assay for maternal serum concentrations of fbeta-hCG and PAPP-A. Fetal nuchal translucency (NT) was measured in the participating centres at a gestational age (GA) of 10-14 weeks. Results of those pregnancies for which a combined biochemical and NT risk was calculated were included in the epidemiological analysis of this study.
RESULTS: A total of 4033 singleton pregnancies were included in the analysis. The median maternal age of the analysed group was 36.5 years. The distribution of GA was biphasic, with median GA of 10.3 and 12.1 weeks, respectively. The detection rate using the combined ultrasound and serum screening at a cut-off level of 1 in 250 was 71% (15/21), with a screen-positive rate of 4.7%.
CONCLUSION: The results of this study show that the first-trimester combined test is suitable as a prenatal screening test in a multi-centre routine clinical setting in the Netherlands. Strict performance evaluation should identify weaknesses in the organisation that impair the performance of the test. Here, the performance of NT was especially identified as a candidate for improvement.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16752435     DOI: 10.1002/pd.1486

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  5 in total

Review 1.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

2.  Gene expression profiling in a mouse model identifies fetal liver- and placenta-derived potential biomarkers for Down Syndrome screening.

Authors:  Jeroen L A Pennings; Wendy Rodenburg; Sandra Imholz; Maria P H Koster; Conny T M van Oostrom; Timo M Breit; Peter C J I Schielen; Annemieke de Vries
Journal:  PLoS One       Date:  2011-04-14       Impact factor: 3.240

3.  Prenatal Diagnostic Testing Following High-Risk Result from Serological Screening: Which Shall We Select?

Authors:  Jing Wang; Xin-Xin Tang; Qin Zhou; Shuting Yang; Ye Shi; Bin Yu; Bin Zhang; Lei-Lei Wang
Journal:  Int J Womens Health       Date:  2021-09-22

4.  Impact of a new national screening policy for Down's syndrome in Denmark: population based cohort study.

Authors:  Charlotte K Ekelund; Finn Stener Jørgensen; Olav Bjørn Petersen; Karin Sundberg; Ann Tabor
Journal:  BMJ       Date:  2008-11-27

5.  Analysis of Down syndrome failed to be diagnosed after prenatal screening: A multicenter study.

Authors:  Tao Jiang; Jie Ding; Xiao-Qing Zhang; Xiao-Juan Zhang; Bin Zhang; Ting Wang; Bin Yu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.